albiglutide (Tanzeum)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Dosage

  • once-weekly injectable

Adverse effects

Mechanism of action

Notes

  • manufactured by GlaxoSmithKline, L.L.C., Wilmington, Del.

More general terms

References

  1. Busko M FDA Approves Weekly Injectable Diabetes Drug: Albiglutide Medscape: April 15, 2014 http://www.medscape.com/viewarticle/823645
  2. FDA News Release: April 15, 2014 FDA approves Tanzeum to treat type 2 diabetes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393289.htm
  3. Prescriber's Letter 21(8): 2014 CHART: Comparison of GLP-1 Agonists Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=300824&pb=PRL (subscription needed) http://www.prescribersletter.com